Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Elironrasib · 1 trial · 3 indications
Incidence and severity of treatment-emergent AEs and serious AEs as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5
Number of patients with clinically significant changes in vital signs
Number of patients with clinically significant changes in clinical laboratory test values
Number of participants with dose limiting toxicities
Number of patients with clinically significant changes in ECGs
Overall response rate per RECIST v1.1 as assessed by blinded independent central review (BICR)
| Arm | Type | Description |
|---|---|---|
| Elironrasib Monotherapy | EXPERIMENTAL | Phase 2 only |
| Daraxonrasib Monotherapy | EXPERIMENTAL | Phase 2 only |
| Daraxonrasib + Elironrasib Combination | EXPERIMENTAL | Phase 1b and 2 |
| Name | Type | Description |
|---|---|---|
| Elironrasib | DRUG | oral tablets |
| Daraxonrasib | DRUG | oral tablets |
Inclusion Criteria: * 18 years of age * Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy 1. Phase 1b Dose Escalation: solid tumors, previously treated 2. Phase 1b Dose Expansion and Phase 2: i. NSCLC, previously t...
Elironrasib is an investigational small molecule being studied for the treatment of Non-Small Cell Lung Cancer (NSCLC). It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated in patients with advanced KRAS G12C mutant solid tumors, including NSCLC.
Elironrasib targets the KRAS G12C mutation, a specific genetic alteration found in certain solid tumors. It is being studied as a monotherapy and in combination with daraxonrasib in patients with advanced KRAS G12C mutant solid tumors, including Non-Small Cell Lung Cancer.
Elironrasib is being developed by Revolution Medicines, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RVMD. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with advanced KRAS G12C mutant solid tumors.
Elironrasib is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received Breakthrough Therapy designation from the FDA for its potential use in treating certain cancers.
Elironrasib is being studied in a Phase 1 clinical trial registered as NCT06128551. This trial is recruiting participants with advanced KRAS G12C mutant solid tumors, including Non-Small Cell Lung Cancer, Colorectal Cancer, and Pancreatic Ductal Adenocarcinoma. The study is being conducted in multiple countries, including the United States and several European nations.
No, Elironrasib is not the same as daraxonrasib. They are two distinct investigational drugs being studied together in a clinical trial. The trial evaluates both drugs as monotherapies and in combination therapy for patients with advanced KRAS G12C mutant solid tumors.